Cargando…
阿帕替尼用于一线治疗进展后晚期非鳞非小细胞肺癌的疗效和生存分析
BACKGROUND AND OBJECTIVE: The efficacy of second or third-line chemotherapy in advanced non-small cell lung cancer (NSCLC) patients is low. The use of targeted drugs brings survival benefit for some patients. Apatinib, as a novel small molecule antiangiogenic drug, has demonstrated satisfactory anti...
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
中国肺癌杂志编辑部
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5973272/ https://www.ncbi.nlm.nih.gov/pubmed/29167006 http://dx.doi.org/10.3779/j.issn.1009-3419.2017.11.07 |